Kinetic analysis and comparison of uptake, distribution, and excretion of 48V-labeled compounds in rats.
Vanadium has been found to be orally active in lowering plasma glucose levels; thus it provides a potential treatment for diabetes mellitus. Bis(maltolato)oxovanadium(IV) (BMOV) is a well-characterized organovanadium compound that has been shown in preliminary studies to have a potentially useful absorption profile. Tissue distributions of BMOV compared with those of vanadyl sulfate (VS) were studied in Wistar rats by using 48V as a tracer. In this study, the compounds were administered in carrier-added forms by either oral gavage or intraperitoneal injection. Data analyzed by a compartmental model, by using simulation, analysis, and modeling (i.e., SAAM II) software, showed a pattern of increased tissue uptake with use of 48V-BMOV compared with 48VS. The highest 48V concentrations at 24 h after gavage were in bone, followed by kidney and liver. Most ingested 48V was eliminated unabsorbed by fecal excretion. On average, 48V concentrations in bone, kidney, and liver 24 h after oral administration of 48V-BMOV were two to three times higher than those of 48VS, which is consistent with the increased glucose-lowering potency of BMOV in acute glucose lowering compared with VS.
Setyawati
I A
IA
Chemsitry Department, University of British Columbia, Vancouver, Canada.
Thompson
K H
KH
Yuen
V G
VG
Sun
Y
Y
Battell
M
M
Lyster
D M
DM
Vo
C
C
Ruth
T J
TJ
Zeisler
S
S
McNeill
J H
JH
Orvig
C
C
D000818:Animals; D003198:Computer Simulation; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics*; D008297:Male; D008954:Models, Biological; D011753:Pyrones / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution; D014638:Vanadates / Q000493:pharmacokinetics*; D017968:Vanadium Compounds / Q000493:pharmacokinetics
D007004:Hypoglycemic Agents; D011753:Pyrones; D017968:Vanadium Compounds; C074212:bis(maltolato)oxovanadium(IV); D014638:Vanadates; C034028:vanadyl sulfate